**UPDATE 6/17/2014: Yesterday morning Titan announced it successfully completed animal tissue studies on May 30, 2014, performing a full cholecystectomy (gallbladder removal) procedure using the SPORT™ surgical system alpha commercial prototype for the required surgical tasks (including grasping, dissecting, mono-polar cautery and suturing). The procedure has been "extensively validated". Aside from the obvious that the animal tissue testing has been completed, the implications are two-fold: (1) the technology is successful and has performed as expected thus far in the process; (2) management has achieved another milestone and continues to meet its goals.
TITXF reached an intraday high of $1.80, and closed up 3.6%. Yesterday's news is important as investors have failed to recognize the disruptive potential and true value...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|